RALEIGH, N.C., June 3 /PRNewswire/ -- CLOSURE Medical Corporation
(Nasdaq: CLSR), at today's annual Stockholder's Meeting announced the key
findings of a pilot clinical study conducted at the University of North
Carolina-Chapel Hill Hospitals and School of Dentistry.  The purpose of this
study was to evaluate the potential of several of CLOSURE's proprietary
cohesive formulations to reduce oral ulcer pain and reduce ulcer healing time.
    The pilot study demonstrated that one of CLOSURE's proprietary
nonabsorbable formulations, when applied to oral ulcers, reduced both
short-term and longer-term pain when compared to the pain experienced by
patients in a control group who were not treated with the device.  The study
further demonstrated that CLOSURE's proprietary formulation significantly
reduced the time required for the ulcer to heal completely when compared to
ulcers which were not treated by CLOSURE's device.  At day seven, 77% of
patients treated with CLOSURE's proprietary formulation experienced complete
healing of their oral ulcer compared to only 21% of patients who did not
receive treatment.
    "We believe that there are about 40 million households within the U.S. in
which one or more members have suffered from oral ulcers within the last
6 months," said Mr. Robert V. Toni, President and CEO of CLOSURE Medical
Corporation.  "CLOSURE's formulation may be able to offer many of these
patients reduced time to complete ulcer healing and relief from the discomfort
associated with these oral ulcers."
    The 42 patient single-center, single-blinded, randomized, controlled,
pilot outpatient clinical trial was conducted at the University of North
Carolina under the direction of Drs. Mark Kutcher, John Ludlow and Allen
Samuelson as approved by the University Investigational Review Board (IRB) and
the General Chemical Research Clinics (GCRC) Committee.
    CLOSURE Medical Corporation develops, commercializes and manufactures
medical cohesive products for wound closure based on its proprietary
cyanoacrylate technology.  CLOSURE's nonabsorbable products may be used to
replace sutures and staples for certain topical wound closure applications,
while its absorbable cohesive products can potentially be used as surgical
sealants and cohesives for internal wound closure and management.  Currently
marketed nonabsorbable tissue cohesive products include DERMABOND, CLOSURE's
non-absorbable cohesive used for certain topical wound closure applications
marketed and distributed exclusively by Ethicon, Inc., a subsidiary of Johnson
& Johnson, Octyldent(R), used in conjunction with antibiotics to treat adult
periodontal disease, and Nexaband(R), a line of topical cohesives used in
veterinary wound closure and management.

    *DERMABOND is a Trademark of Ethicon, Inc., a subsidiary of Johnson &
Johnson.

    This release contains certain forward-looking statements which involve
known and unknown risks, delays, uncertainties or other factors not under the
Company's control which may cause actual results, performance or achievements
of the Company to be materially different from the results, performance, or
other expectations implied by these forward-looking statements.  These factors
include, but are not limited to, the early stage of commercialization of the
Company's products; scale-up of manufacturing processes; the need for
regulatory approval and effects of governmental regulation; technological
uncertainties; dependence on marketing partners; and dependence on patents and
trade secrets, as well as those detailed in the Company's Annual Report on
Form 10-K for the year ended December 31, 1997 and filed with the Securities
and Exchange Commission.

Link to this page: